Blueprint medicines' continued leadership in redefining the standard of care in systemic mastocytosis highlighted at 2024 ash annual meeting

-- ash data reinforce survival benefits of front-line ayvakit® (avapritinib) use in patients with advanced sm -- -- bone density analyses reported in patients with advanced sm underscore disease-modifying effects of ayvakit --  cambridge, mass. , dec. 7, 2024 /prnewswire/ -- blueprint medicines corporation (nasdaq: bpmc) today announced data presentations that continue to demonstrate the long-term clinical benefits of ayvakit® (avapritinib) in advanced systemic mastocytosis (advanced sm), and reflect the company's ongoing partnership with the sm community to redefine the future of patient care – from improving diagnostic rates to raising the bar on treatment outcomes.
ASH Ratings Summary
ASH Quant Ranking